Notícias

One turnaround play is bleeding cash, while the other is unprofitable but growing fast. The financial reality behind this choice is more nuanced than valuation alone.

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

One trades at a 14.9x forward P/E with negative free cash flow; the other is burning $321.8 million annually.

Ondas' $205M GATE deal expands its defense footprint, adding ESAD expertise and manufacturing capabilities as loitering munitions demand grows.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

One highly ranked investor says the company remains compelling, but the stock may need a much lower entry point.

IREN raised expected 2026 ARR to $4.0 billion from $3.4 billion in November

Coca-Cola just outpaced the S&P 500 by a wide margin and sits near all-time highs, but one operating metric buried beneath the EPS headlines will determine whether the rally holds or quietly falls apart.

RTX has a record backlog, rising defense orders, and surging commercial aerospace demand. Lucid has a promising new vehicle and a long road to profitability.

CNC's and ADM's strong 2026 guidance, estimate revisions and attractive valuations offer fresh reasons to watch these non-AI stocks.

Applied Materials trades at a steep valuation premium, while Qualcomm's cheaper multiple masks exposure to customer concentration and geopolitical risk.

EMR, NDSN and ZBRA offer double-digit short-term upside, backed by automation demand and solid growth prospects.

The three are found in the IBD Stock Screener, specifically the list of Stocks That Funds Are Buying.

Micron and Sandisk have been some of the biggest winners over the past year, and these AI stocks may be next.

Investing.com -- Citi told investors in a note Tuesday that the recent pullback in semiconductor stocks looks like a buying opportunity, arguing that fears of an AI spending slowdown are overdone.

Rwanda will contribute the Shyorongi exploration concession and a mineral processing licence as part of the tungsten partnership.

DeFi Development Corp added another 55,491 SOL and opened a CHAD at-the-market program for its preferred stock, extending a fast-moving three-week run of capital markets activity.

Oracle stock is down more than 50% from its high. Is this a buying opportunity?

DoorDash will continue to expand Grubhub’s former campus dining operations, and Wonder will use money from the deal and an investment to sustain growth.

Software moved against the chip tape on September 14. Workday, Inc. (NASDAQ:WDAY) and Adobe Inc. (NASDAQ:ADBE) rose roughly 2.5% to 3% as chip stocks fell following calls to slow frontier AI development. The market has spent much of the year asking whether stronger models make incumbent software obsolete. A slower frontier suddenly makes the opposite question […]

By Purvi Agarwal, Sruthi Shankar and Medha Singh Sept 15 (Reuters) - Add the summer bond-market rout to the list of market upheavals that U.S. stocks have largely shrugged off.

The Tilray bull case is getting stronger without U.S. legalization.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

AI's growing power needs could become a long-term opportunity for these three nuclear stocks.

VLO, SNDR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 15th, 2026.

The asset manager funded the entire purchase through preferred stock, pushing SATA's notional value past $1 billion for the first time.

BFH, HCSG and MTG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 15th, 2026.

This exchange-traded fund exclusively invests in America's largest growth companies.

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car